title: [Non-invasive assessment of fatty liver].
abstract: As the result of various harmful effects (infectious agents, metabolic diseases, unhealthy diet, obesity, toxic agents, autoimmune processes) hepatic damage may develop, which can progress towards liver steatosis, and fibrosis as well. The most common etiological factors of liver damages are hepatitis B and C infection, alcohol consumption and non-alcoholic fatty liver disease. Liver biopsy is considered as the gold standard for the diagnosis of chronic liver diseases. Due to the dangers and complications of liver biopsy, studies are focused on non-invasive markers and radiological imaging for liver steatosis, progression of fatty liver, activity of the necroinflammation and the severity of the fibrosis. Authors review the possibilities of non-invasive assessment of liver steatosis. The statistical features of the probes (positive, negative predictive values, sensitivity, specificity) are reviewed. The role of radiological imaging is also discussed. Although the non-invasive methods discussed in this article are useful to assess liver steatosis, further studies are needed to validate to follow progression of the diseases and to control therapeutic response.
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088.
authors.forename: Anna
authors.initials: A
authors.lastname: Egresi
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lengyel
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088.
authors.forename: Krisztina
authors.initials: K
authors.lastname: Hagymási
mesh_terms: D000428:Alcohol Drinking / Q000009:adverse effects; D017209:Apoptosis; D015415:Biomarkers / Q000097:blood*; D001706:Biopsy / Q000009:adverse effects; D015992:Body Mass Index; D002908:Chronic Disease; D018450:Disease Progression; D005234:Fatty Liver / Q000097:blood / Q000175:diagnosis* / Q000209:etiology* / Q000473:pathology / Q000821:virology; D005355:Fibrosis / Q000097:blood / Q000175:diagnosis; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000175:diagnosis; D008099:Liver / Q000473:pathology*; D008107:Liver Diseases / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D064847:Multimodal Imaging; D009336:Necrosis / Q000097:blood / Q000175:diagnosis; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications; D009765:Obesity / Q000150:complications; D018384:Oxidative Stress; D011237:Predictive Value of Tests; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography / Q000379:methods
chemical_list: D015415:Biomarkers
keywords: fatty liver; képalkotó eljárások; liver steatosis; májelzsírosodás; nem invazív próbák; non-invasive methods; radiological imaging; steatosis hepatis